Skip to main content

Table 1 Demographic and clinical characteristics at screening (primary analysis set)

From: Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy

 

Placebo-etanercept (N = 104)

Etanercept-etanercept (N = 106)

All patients (N = 210)

Age, mean years (SD)

55.5 (12.8)

56.5 (12.1)

56.0 (12.4)

Sex, n women (%)

86 (82.7)

75 (70.8)

161 (76.7)

Race, n (%)

   

 White

90 (86.5)

91 (85.8)

181 (86.2)

 Black/African American

8 (7.7)

9 (8.5)

17 (8.1)

 Asian

3 (2.9)

2 (1.9)

5 (2.4)

 Other

3 (2.9)

4 (3.8)

7 (3.3)

BMI, mean kg/m2 (SD)

29.3 (6.6)

30.6 (7.7)

30.0 (7.2)

Duration of RA, mean years (SD)

7.4 (8.1)

8.3 (11.2)

7.8 (9.8)

DAS28-CRP, mean (SD)

4.9 (0.8)

4.9 (0.7)

4.9 (0.8)

  1. SD: standard deviation; BMI: body mass index; RA: rheumatoid arthritis; DAS28-CRP: Disease Activity Score based on 28 joints with C-reactive protein.
Back to article page